{"entity":{"id":"majic-pv","kind":"trial","name":"MAJIC-PV","aka":[],"tldr":"MAJIC-PV, a UK academic trial, found that ruxolitinib gave more complete responses than best available therapy and, for the first time, that a complete response went with fewer clots and progressions.","summary":"MAJIC-PV randomised 180 patients with PV resistant to or intolerant of hydroxyurea to ruxolitinib or best available therapy. Complete response within a year, the primary endpoint, was reached by 43 percent on ruxolitinib versus 26 percent on best available therapy; complete responders had better event-free survival (thrombosis, haemorrhage, transformation or death), and the JAK2 V617F allele burden fell more on ruxolitinib (Harrison and colleagues, Journal of Clinical Oncology 2023). Registered as ISRCTN61925716.","status":"positive","asOf":"2026-09-16","links":[{"label":"ISRCTN61925716","url":"https://www.isrctn.com/ISRCTN61925716"},{"label":"JCO 2023","url":"https://doi.org/10.1200/JCO.22.01935"}],"tags":["polycythaemia-vera","mpn"],"related":[],"cancers":["polycythaemia-vera"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["ruxolitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-harrison-j-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"phase":"2","setting":"Hydroxyurea-resistant or intolerant polycythaemia vera: ruxolitinib versus best available therapy","sponsor":"University of Birmingham (UK)","result":"Complete response within 1 year: 43% vs 26%; complete response associated with better event-free survival.","yearReported":2023,"enrolled":180,"enrolledBasis":"registry","outcomes":[{"endpoint":"Complete response within 1 year","primary":true,"unit":"%","arms":[{"name":"Ruxolitinib","n":93,"value":43},{"name":"Best available therapy","n":87,"value":26}]}]},"route":"/trials/majic-pv/","neighbours":{"cancer":[{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"}],"paper":[{"id":"paper-harrison-j-clin-oncol","kind":"paper","name":"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial","route":"/key-papers/paper-harrison-j-clin-oncol/"}],"idea":[{"id":"idea-pv-clone-directed-therapy","kind":"idea","name":"Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission","route":"/ideas/idea-pv-clone-directed-therapy/"}]}}